NASDAQ:AFMD

Affimed N.V. Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Biotechnology

$4.00

+0.130 (+3.36%)

At Close: Sep 13, 2024

Affimed N.V. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 AFMD shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Golden Star

Ticker	Date	Change	Price
ZI	Sep 11	8.37%	$9.80
EPD	Sep 11	1.61%	$29.15
AGR	Sep 11	0.364%	$35.75
ALGN	Sep 11	8.25%	$225.15
WTS	Sep 10	1.47%	$191.70
BXSL	Sep 10	1.31%	$29.87
SILK	Sep 10	1.14%	$27.19
CORT	Sep 09	9.83%	$34.70
FTSL	Sep 06	0.436%	$45.89
ARR	Sep 05	2.47%	$20.26

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In